Bavarian Nordic (OTCMKTS:BVNRY) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Bavarian Nordic (OTCMKTS:BVNRY) saw unusually-high trading volume on Friday . 3,010 shares traded hands during trading, a decline of 8% from the previous session’s volume of 3,265 shares.The stock last traded at $10.5352 and had previously closed at $10.4960.

Bavarian Nordic Stock Up 0.4%

The business’s 50 day moving average is $9.84 and its 200-day moving average is $9.77. The firm has a market capitalization of $2.50 billion, a P/E ratio of 10.64 and a beta of 1.20.

Bavarian Nordic (OTCMKTS:BVNRY) last announced its quarterly earnings data on Friday, August 21st. The company reported $0.46 EPS for the quarter. The business had revenue of $316.47 million during the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 12.06%.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.